ClinVar Miner

Submissions for variant NM_000492.4(CFTR):c.2490+1G>T

dbSNP: rs141158996
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Johns Hopkins Genomics, Johns Hopkins University RCV001250517 SCV001425311 pathogenic Cystic fibrosis 2020-03-09 criteria provided, single submitter clinical testing CFTR c.2490+1G>T has been previously identified in a patient with cystic fibrosis. This CFTR variant (rs141158996) is rare (<0.1%) in a large population dataset (gnomAD: 1/190386 total alleles; 0.0005%; no homozygotes). This variant destroys a canonical splice donor site and is predicted to cause abnormal gene splicing. We consider this variant to be pathogenic.
Labcorp Genetics (formerly Invitae), Labcorp RCV001250517 SCV003480730 pathogenic Cystic fibrosis 2022-06-10 criteria provided, single submitter clinical testing Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 973859). This variant is also known as c.2622+1G>T. Disruption of this splice site has been observed in individuals with cystic fibrosis (PMID: 7683952, 9239681, 12815607, 20059485, 23974870). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This sequence change affects a donor splice site in intron 14 of the CFTR gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CFTR are known to be pathogenic (PMID: 1695717, 7691345, 9725922).
Baylor Genetics RCV004570640 SCV005057413 pathogenic Bronchiectasis with or without elevated sweat chloride 1 2024-03-20 criteria provided, single submitter clinical testing
PreventionGenetics, part of Exact Sciences RCV004538530 SCV004712081 pathogenic CFTR-related disorder 2023-12-21 no assertion criteria provided clinical testing The CFTR c.2490+1G>T variant is predicted to disrupt the GT donor site and interfere with normal splicing. This variant was reported in individuals undergoing genetic testing for cystic fibrosis (referred to as c.2622+1G>T in Scotet et al. 2003. PubMed ID: 12815607; Table S4, Raraigh et al. 2021. PubMed ID: 34782259). This variant is reported in 0.0011% of alleles in individuals of European (non-Finnish) descent in gnomAD and is interpreted as pathogenic in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/973859/). Variants that disrupt the consensus splice donor site in CFTR are expected to be pathogenic. This variant is interpreted as pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.